ER

Baxter to acquire Gambro, enhance renal therapies portfolio

Wednesday, December 5, 2012 10:40 AM

Baxter International, a global healthcare company, has entered into a definitive agreement to acquire Gambro, a privately held dialysis product company based in Lund, Sweden, for total consideration of approximately $4 billion.

More... »

ALS TDI, Gladstone Institutes to discover potential ALS treatments

Wednesday, December 5, 2012 09:44 AM

The ALS Therapy Development Institute (ALS TDI), aimed at developing effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS), and the Gladstone Institutes, a nonprofit biomedical-research organization, have formed a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.

More... »

Omeros appoints Mitro as vice president, sales and marketing

Tuesday, December 4, 2012 08:00 AM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company focused on products targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed Thomas A. Mitro as vice president of sales and marketing.

More... »

NextPharma completes sale of U.S. affiliate

Monday, December 3, 2012 12:44 PM

NextPharma Technologies Holding, a contract manufacturer in Europe, has completed the sale of Bioserv, its U.S. affiliate based in San Diego, to KESA Partners.

More... »

PAREXEL, NTUH to support clinical research in Taiwan

Monday, December 3, 2012 12:17 PM

PAREXEL International, a global biopharmaceutical services provider, and the National Taiwan University Hospital (NTUH) have established a collaboration to provide drug development services in Taiwan.

More... »

Ampio Pharmaceuticals names Disbrow as COO

Friday, November 30, 2012 11:45 AM

Ampio Pharmaceuticals, a Greenwood Village, Colo.-based biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, has appointed Josh Disbrow as chief operating officer.

More... »

Pfizer acquires NextWave Pharmaceuticals

Thursday, November 29, 2012 01:49 PM

Pfizer has completed its acquisition of NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

More... »

Chiltern promotes Aize Smink and Linda Christmas

Thursday, November 29, 2012 08:00 AM

Chiltern International, a global CRO, has promoted Aize Smink and Linda Christmas to executive positions, coinciding with Dr. Jim Esinhart’s appointment as CEO.

More... »

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »

IntelliCell BioSciences inks research agreement with Rutgers’ N.J. Center for Biomaterials

Wednesday, November 28, 2012 11:16 AM

IntelliCell BioSciences, a regenerative medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs, has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers, the state university of New Jersey.

More... »